IDE Group

Banner Image

Pictured: Retina of a patient with diabetic retinopathy. Photo by IDE Group.

Project title: A novel device and injectable solution to treat ocular diseases

Aged macular degeneration (AMD) is the leading cause of blindness in Australia, affecting 1 in 7 people over the age of 50. 

The current treatment for AMD and other ocular diseases such as Diabetic Retinopathy, involves ongoing monthly injections of anti-vascular endothelial growth factor drugs to the back of the eye, which is both costly and invasive. 

IDE Group in partnership with CSIRO has developed a combination drug delivery-device system to improve the clinical challenges of delivering therapeutics to the eye, while also improving the drug delivery and thereby reducing the frequency of injections. This project aims to identify a target drug, design and develop a prototype and demonstrate effectiveness in vivo in an animal study.

BMTH Round: Two

State: New South Wales

Project partner: CSIRO


  • MTPConnect Grant: $1,000,000
  • Industry Contribution: $1,412,065

Duration: April 2020 - September 2022

Visit IDE Group for more information  |  Twitter: ide_group  |  LinkedIn: ide group

Contact: Kirsty Amland